Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Elan Corporation plc recently received more visibility regarding its proposed takeover by Royalty Management LLC (Royalty Pharma). The Irish Takeover Panel recently extended the deadline on Royalty Management LLC to May 10, 2013.

As per the imposition by the Irish Takeover Panel, Royalty Pharma must either make an offer to Elan under rule 2.5 of the Irish Takeover Rules or must notify that it will not proceed with the same by May 10, 2013.

Notably, in Feb 2013, Royalty Pharma showed interest in acquiring Elan at $11 for every share of Elan and its American Depositary Shares (ADS). We note that 1 ADS is equal to 1 share of Elan. Royalty Pharma’s offer represented a premium of 6.3% to Elan’s closing price on Feb 15, 2013.

In its latest press release Elan stated that it will take into consideration any credible proposal from Royalty Pharma or any other company alongside the strategic transactions. We expect investor focus to remain on Royalty Pharma’s offer going forward.

Meanwhile, Elan recently closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec (BIIB - Analyst Report). As a result, Biogen gained full strategic, commercial and operational control over the multiple sclerosis drug.

We believe that the loss of Tysabri is a huge setback for Elan since the product was its primary source of revenue. Elan, a biotechnology company, currently carries a Zacks Rank #5 (Strong Sell). The bearish rank is largely due to the setback.

Currently, well-placed biotech stocks include Cytokinetics Inc. (CYTK - Snapshot Report) and QLT Inc. (QLTI - Analyst Report). Both stocks carry a Zacks Rank #1 (Strong Buy). Biogen also carries a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ANI PHARMACE ANIP 29.57 +15.73%
ALLIANCE FIB AFOP 17.94 +3.58%
ATLAS FINANC AFH 14.67 +3.02%
GENTHERM INC THRM 36.59 +2.05%
FEDERATED NA FNHC 20.26 +1.96%